Compare FEMY & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEMY | VTGN |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 9.5M |
| IPO Year | 2021 | 2014 |
| Metric | FEMY | VTGN |
|---|---|---|
| Price | $1.22 | $0.17 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $14.75 | $1.00 |
| AVG Volume (30 Days) | 104.8K | ★ 730.6K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,293,313.00 | N/A |
| Revenue This Year | N/A | $33.96 |
| Revenue Next Year | $294.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.77 | N/A |
| 52 Week Low | $0.29 | $0.17 |
| 52 Week High | $6.29 | $5.14 |
| Indicator | FEMY | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 40.45 |
| Support Level | $0.33 | $0.17 |
| Resistance Level | $1.55 | $0.32 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 36.46 | 14.91 |
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.